GORD208

GORD208 is a preclinical-stage small molecule inhibitor of Protein Arginine Methyltransferases (PRMTs), developed by Gordion Bioscience and licensed to Kohde Pharma. The drug is designed to treat cancers characterized by the deletion of the Methylthioadenosine Phosphorylase (MTAP) gene. This therapeutic approach leverages synthetic lethality, a strategy where the genetic loss of MTAP renders tumor cells selectively vulnerable to the inhibition of PRMT enzymes. Gordion Bioscience utilizes a platform combining machine learning with patient-derived tumor data to identify and validate such targets, focusing on simultaneous inhibition of primary drug targets and their compensatory mechanisms.